Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (DGX) provides essential diagnostic insights and testing services across the U.S. healthcare system. This news hub aggregates official press releases, financial updates, and strategic developments from one of America's leading clinical laboratory networks.
Investors and healthcare professionals will find timely updates on earnings reports, partnership announcements, and technological advancements in diagnostic testing. Our curated news feed includes regulatory milestones, service expansions, and innovations leveraging DGX's vast clinical database.
Key updates cover emerging trends in precision diagnostics, laboratory network growth, and healthcare collaborations. Users can track the company's progress in cancer detection, genomic testing, and data-driven health solutions through verified primary sources.
Bookmark this page for direct access to DGX's latest financial performance data, leadership changes, and operational developments. Visit regularly to stay informed about how Quest Diagnostics continues shaping diagnostic medicine through clinical excellence and strategic initiatives.
Quest Diagnostics celebrated Lab Week 2024 across the nation. The event featured the professional journeys of colleagues, like Javarus Smith, who progressed from Route Service Representative to Logistics Manager. Javarus emphasized the impact of their work on patients' lives and encouraged flexibility for career growth within Quest. The company's commitment to customer service, care, collaboration, continuous improvement, and curiosity was highlighted.
Quest Diagnostics received high praise from a patient at their Voorhees PSC location in New Jersey, highlighting exceptional staff service and professionalism. The team's dedication and consistent excellent service reflect the company's core values. The positive feedback showcases a strong commitment to customer care and satisfaction.
Quest Diagnostics, a leading diagnostic information services company, will have its CEO speak at the 2024 Leerink Partners Healthcare Crossroads Conference. The event will cover the company's strategy, performance, and market trends, with a live webcast available for investors.
Quest Diagnostics and PathAI announced a collaboration to accelerate the adoption of digital and AI pathology innovations to improve cancer diagnosis. Quest will acquire select assets of PathAI Diagnostics to enhance its AI and digital capabilities. The transaction is expected to be completed in the second quarter of 2024. Additionally, Quest will license PathAI's AISight™ digital pathology image management system to support its pathology laboratories and customer sites in the U.S.
Quest Diagnostics has appointed Murali Balakumar as the Senior Vice President and Chief Information and Digital Officer, bringing 25 years of experience in technology strategy across healthcare, financial services, and transportation industries. As a digital transformation leader, Mr. Balakumar will oversee information technology, data informatics, and digital solutions for the company.
Quest Diagnostics collaborated with St. James Health to offer no-cost Blueprint for Wellness screenings during a Choose Healthy Life event at the Metropolitan Baptist Church in Newark. The event celebrated the expansion of the Willing Heart Community Care Center, supported by the Quest Diagnostics Foundation. The initiative aims to address social inequities in healthcare, employment, housing, and poverty. Quest provided 51 attendees with Blueprint for Wellness screenings, showcasing their commitment to health equity in underserved communities.
Quest Diagnostics and PathAI announced a collaboration to accelerate AI and digital pathology adoption in cancer diagnosis. Quest will acquire certain assets of PathAI Diagnostics to enhance its AI and digital capabilities. The transaction includes licensing agreements and is expected to close in Q2 2024. The partnership aims to improve cancer care quality and efficiency with cutting-edge technologies.
FAQ
What is the current stock price of Quest Diagnostics (DGX)?
What is the market cap of Quest Diagnostics (DGX)?
